Background: Endometriosis is a benign disease that has malignant properties such as genetic polymorphism, loss control of cell proliferation, infiltration, and local spread or to distant places. Several endometriosis studies linking endometrioma/ ovarian endometriosis with an increased risk of ovarian malignancy give rise to a transformation phenomenon of endometriotic cysts into malignancy. Bax is a pro apoptotic protein whose expression decreases in a malignancy. This decrease is related to the poor prognosis of endometrioma and ovarian carcinoma. This study was aimed to identify the expression and the difference of Bax expression between endometrioma and ovarian carcinoma.Materials and Methods: Fifty of paraffin blocks of endometrioma tissue and ovarian carcinoma (serous, mucinous, clear cell, and endometrioid type) were examined by immunohistochemical using Bondmax Full Automatic with specific monoclonal antibody to identify Bax expression. The difference of Bax expression score between endometrioma tissue and ovarian carcinoma was tested by Mann-Whitney test with significant value was set at p<0.05.Results: This study found that mean Bax expression score in endometrioma tissue and ovarian carcinoma was 3.88 and 3.72. No difference of Bax expression between endometrioma tissue and ovarian carcinoma (p>0.05). No difference of Bax expression between the clinical stages and histopathological types of ovarian carcinoma (p>0.05).Conclusion: There are no statistically significant difference in Bax protein expression in ovarian cancer and endometrioma.Keywords: Bax expression, endometrioma, ovarian carcinoma, apoptotic resistance
RESEARCH RESEARCH Background. Glutathione peroxidase (GPx) is one of the antioxidant enzymes that maintain the balance of reactive oxygen species. GPx has a notable role in the progression of cancer, including ovarian cancer. Synthesis of this enzyme may be down-regulated in cases of ovarian cancer. As far as we are aware, this has not been studied in an Indonesian population. Objective. To identify the difference in serum GPx levels between ovarian cancer patients and healthy controls. Methods. This was an observational analytical study with a case-control design. The study was conducted in the Department of Obstetrics and Gynaecology at the Haji Adam Malik Hospital in Medan, Indonesia. Serum GPx levels were measured in 20 ovarian cancer patients and 20 control subjects. Results. The types of ovarian cancer identified by histopathology in this study included serous adenocarcinoma (n=10; 50%) and various non-serous adenocarcinomas (50%). The mean (SD) serum GPx level was significantly lower in the cancer group (295.235 (244.479) mU/mL) than in the control group (743.546 (131.949) mU/mL) (p<0.0008). The median serum GPx level was lower among patients with serous ovarian cancer (209.915 mU/mL) than among those with non-serous ovarian cancer (338.885 mU/mL), although the difference was not statistically significant (p>0.226). Conclusion. Serum GPx levels were found to be significantly lower in patients with ovarian cancer than in healthy controls. Further studies are needed to determine an appropriate cutoff level for serum GPx in ovarian cancer in this population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.